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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT?
• In the USA psycho-stimulant use has
increased rapidly in the 1990s and stabilized
around 2000.
• This study describes the prevalence of
psycho-stimulant use between1996 and
2006 in the Netherlands.
WHAT THIS STUDY ADDS
• The prevalence of psycho-stimulant use
among youth in the Netherlands has
increased more than eightfold in the period
1996–2006, but in 2006 it is still below the
prevalence in the USA.
AIM
To describe the use of psycho-stimulants in the Netherlands between
1996 and 2006 in children and adolescents, and in relation to age and
sex.
METHODS
With the pharmacy prescription database the IADB.nl, yearly
prevalences of psycho-stimulants per 1000 children were calculated, as
was the length of psycho-stimulant use with Kaplan–Meier method in
SPSS 12.0.
RESULTS
Psycho-stimulant use increased in boys (0–19) from 4.5‰ in 1996 to
31.1‰ in 2006 and for girls from 0.7 to 8.1‰, respectively. The largest
increase was among boys aged 10–19 years. There is a trend towards
prescribing the sustained release preparation of methylphenidate
(Concerta).
CONCLUSIONS
In the Netherlands a large increase in psycho-stimulants use is
observed. However, in the Netherlands the prevalence ratio
male/female declined from 6.4 in 1996 to 3.8 in 2006.
Introduction
The high increase in psycho-stimulant use in the 1990s has
led to widespread discussion about the frequent use of
psycho-stimulants in children and adolescents in the USA
and Europe. In 2002 the use of psycho-stimulants among
US children aged 0–19 years ranged between 3 and 4.3%.
[1,2] There were concerns about side-effects, risks and long
term outcome, but also about under-recognition of treat-
ment needs and underdiagnosis of hyperactivity disorders.
Despite this, the use of psycho-stimulants increased, as in
the Netherlands [3]. Since physicians in the Netherlands
are known to be more restrictive in prescribing drugs [3, 4],
one might question if this increase in psycho-stimulant use
as seen in the USA is also noticeable in the Netherlands.
This study describes the prevalence and duration of use
of psycho-stimulants in children and adolescents in the
Netherlands from 1996 to 2006, in relation to age and sex.
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Methods
For this study the IADB.nl (www.iadb.nl) was used, which
contains prescription drug-dispensing data from the Neth-
erlands. The estimated population size covered by the
IADB.nl increased from 62 000 aged 0–19 years in 1996 to
approximately 120 000 aged 0–19 years in 1999 and has
remained stable since. The database includes all prescrip-
tions, regardless of prescriber, insurance or reimbursement
status, except over-the-counter drugs and drugs dis-
pensed during a hospital stay. Each prescription record
comprises information about the drug, date of dispensing,
amount dispensed, dose regimen and the prescribing phy-
sician. All drugs are coded according to the Anatomical
Therapeutic Chemical (ATC) classification [5]. Each patient
has a unique, although anonymous, identifier. Due to a
high patient pharmacy commitment in the Netherlands
and sophisticated pharmacy software, the medication
records for each patient are virtually complete [6].
During the study period 1996–2006 we selected all
children and adolescents (0–19 years) with at least one
psycho-stimulant prescription (ATC code N06BA). Atten-
tion deficit hyperactivity disorder (ADHD) medications
prescribed were methylphenidate, methylphenidate sus-
tained release and, less frequently, atomoxetine.
The yearly prevalence (1996–2006) of stimulant use
was calculated per 1000 with 95% confidence intervals
(CIs) for all children and adolescents 0–19 years old and per
age category (0–4, 5–9, 10–14 and 15–19 years) and sex.
To test whether the duration of psycho-stimulant use
changed over this period, children and adolescents who
started to use medication in the period 1996–1999 were
compared with those who started between 2001 and
2004. Children and adolescents were regarded starters
if they had not had any stimulant prescription before,
despite being registered for 6 months in the database.
Duration of stimulant use was estimated for all incident
users using the Kaplan–Meier survival estimator. Stimulant
treatment was considered stopped when a child had not
received prescribed stimulants for100 consecutive days
after the theoretical end date of the final prescription. Cox
proportional hazard ratio (HR) with 95% CIs was used to
calculate the difference between two cohorts. Statistical
analyses were performed in SPSS 12.0 for Windows (SPSS
Inc., Chicago, IL, USA). Analogously, duration of use is
described for male and female users for the whole period
1996–2006.
Results and discussion
Use of psycho-stimulants had increased among children
and adolescents (0–19 years) between 1996 and 2006 from
2.6/1000 to 19.5/1000. The use among boys (0–19 years)
increased from 4.5 (3.8–5.3) to 31.1 (29.8–32.5) per 1000
and among girls (0–19 years) from 0.7 (0.5–1.1) to 8.1 (7.4–
8.8) per 1000. In 2006 the use of psycho-stimulants among
preschoolers (0–4-year-olds) was very low (1/1000 in boys
and 0.2/1000 in girls). In 2006, 6.1% (95% CI 5.7, 6.5) of the
boys aged 10–14 years and 1.5% (95% CI 1.3, 1.7) of the
girls in the same age category received at least one pre-
scription per year for a stimulant. There are significantly
more male than female psycho-stimulant users, although
the prevalence ratio male/female fell from 6.4 in 1996 to
3.8 in 2006. (See Table 1 for the other age categories.)
However, this prevalence ratio male/female is smaller com-
pared with studies from other countries (range 8–10). This
suggests more awareness of and attention to ADHD in girls
among physicians and parents in the Netherlands.
Noteworthy was a shift of highest use in 5–9-year-olds
in 1996 to highest use in 10–14-year-olds in 2006. A shift in
Table 1
Psycho-stimulant use among Dutch 0–19-year-olds between the years 1996 and 2006. Prevalence per 1000, related to age and sex
Age, years 1996 1999 2003 2006
0–4 Pop. male/female 7 355/7 139 13 421/12 868 15 512/15 035 15 839/14 769
prev. male/1000 0.8 (0.3, 1.8) 1.54 (0.9, 2.3) 1.2 (0.7, 1.8) 1.0 (0.5, 1.5)
prev. female/1000 0.1 (0.0, 0.8) 0.5 (0.2, 1.1) 0.1 (0.0, 0.5) 0.2 (0.0, 0.6)
Pop. male/female 7 600/7 628 13 367/13 086 13 795/13 203 14 966/14 309
5–9 prev. male/1000 8.8 (6.8, 11.2) 29.0 (26.2, 32.0) 23.6 (21.1, 26.3) 35.5 (32.6, 38.6)
prev. female/1000 1.2 (0.5, 2.2) 5.3 (4.1, 6.7) 6.8 (5.5, 8.4) 8.5 (7.1, 10.2)
Pop. male/female 7 961/7 686 13 167/13 068 13 520/13 571 14 306/14 921
10–14 prev. male/1000 6.7 (5.0, 8.7) 28.7 (25.9, 31.7) 46.4 (43.0, 50.1) 60.7 (56.8, 64.7)
prev. female/1000 1.2 (0.5, 2.2) 5.1 (3.9, 6.4) 10.7 (9.0, 12.6) 14.5 (12.6, 16.5)
Pop. male/female 8 666/8 494 15 641/15 612 15 898/16 116 16 608/17 736
15–19 prev. male/1000 2.0 (1.1, 3.1) 9.3 (7.8, 10.9) 21.0 (18.8, 23.4) 30.4 (27.8, 33.1)
prev. female/1000 0.4 (0.1, 1.0) 1.9 (1.2, 2.7) 4.8 (3.8, 6.0) 8.9 (7.6, 10.4)
All ages:
0–19 Pop. male/female 31 582/30 947 55 596/54 634 58 725/57 925 61 719/61 735
prev. male/1000 4.5 (3.8, 5.3) 16.7 (15.7, 17.9) 22.2 (21.1, 23.5) 31.1 (29.8, 32.5)
prev. female/1000 0.7 (0.5, 1.1) 3.1 (2.7, 3.6) 5.4 (4.8, 6.1) 8.1 (7.4, 8.8)
Prevalences per 1000. 95% confidence intervals in parentheses.
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prevalence towards higher use in older age groups could
be related to an increased duration of use in recent years.
We observed a shorter duration of use in children and
adolescents who started in the period 1996–1999 with
stimulants compared with those who started between
2001 and 2004 (HR 0.84, 95% CI 0.75, 0.93).We also found a
significant difference in duration of use between boys and
girls presented in Figure 1 (HR 1.30, 95% CI 1.14, 1.48,
adjusted for calendar year).
In recent years, there was a trend towards prescribing
the extended-release psycho-stimulants that were intro-
duced in 2003, instead of the immediate-release meth-
ylphenidate among all ages in more recent years. In 2006
approximately 30% of all stimulant prescriptions were
sustained-release methylphenidate. Atomoxetine, which
was introduced in 2002, accounted for <5% of prescrip-
tions. The observed changes indicate that more children
and also older children and girls receive treatment with
medication for ADHD. A possible explanation may be more
awareness of ADHD among physicians and parents. A limi-
tation is that information about diagnoses is lacking.
However, previous studies have shown that in 92% of
stimulant users it was prescribed for ADHD [3].
Conclusions
Among Dutch children and adolescents aged 0–19 years
we found a significant increase in the use of psycho-
stimulants from 2.6 per 1000 in 1996 to 19.5 per 1000 in
2006. Use in boys increased from 0.45 to 3.1% (a sixfold
increase), but less markedly so in girls from 0.07 to 0.8% (a
12-fold increase).These increases can be attributed to new
use, the use of recently introduced preparations and use in
older children. The use of stimulants among preschoolers
is nil. Compared with the USA, the prevalence of use in
Dutch children and adolescents in 2006 is below that
among US children aged 0–19 years even when compared
with 2002, when it ranged between 3 and 4.3% [1, 2].These
lower prescribing rates might reflect under-recognition of
ADHD in the Netherlands. Safety studies on long-term use
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Duration of stimulants drug use for boys (blue) and girls (green) who
started therapy between 1996 and 2003. (Kaplan–Meier survival curve,
+ are censored data)
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